Prevalence of cardiovascular compromise in patients hospitalized for COVID-19.
Article Sidebar
Main Article Content
Abstract
Introduction. Of hospitalized patients with Covid-19 infection, they have a mortality of 10-15%, and can reach 40-50% in severe forms. These patients can develop cardiovascular complications, myocardial damage (7-28%) and thrombosis (17.5%) being the most frequent, associated with a risk of hospital adverse events (need for mechanical ventilation, arrhythmias and death).
Objetive. Determine the prevalence of cardiovascular complications in Covid-19, identify these complications, and determine the risk factors for short-term mortality.
Materials and methods. Retrospective cohort study, including patients who were admitted to our institution with a diagnosis of Covid-19 infection, from January 2020 to May 2021. Cardiovascular events were considered myocardial injury, myocardial infarction, pulmonary embolism, Deep Vein Thrombosis, Cerebrovascular Accident, syncope and myocarditis.
Results. 625 patients diagnosed with Covid-19 who were hospitalized within a period of 16 months were included. The prevalence of cardiovascular complications in these patients was 28.7%, the most frequently found being myocardial injury (23.5%), followed in frequency by TEPA (2.6%), DVT (1.4%), AMI (0.2%), stroke (0.3 %), syncope (0.5%) and myocarditis (0.2%). Of the patients who presented myocardial injury, 77.6% required ARM, and 85.5% died. Overall mortality was 10.9%.
Conclusion: The development of cardiovascular complications was higher in patients with a previous cardiovascular history, the elevation of cardiac biomarkers such as hs-TnT was associated with a worse prognosis, with a greater progression towards death and/or MRA requirement. Arterial hypertension and the condition of overweight and obesity were identified as predictors of mortality in the first place.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The magazine does not retain the reproduction rights (copyright) so the authors can republish their works with the sole mention of the original publication source.
References
- Spyropoulos A.C. Coagulopathy in COVID-19: What are the Venous Thromboembolism (VTE) Prevention and Treatment Guidelines. VuMedi [internet], 2021 https://www.vumedi.com/video/coagulopathy-in-covid-19-what-are-the-venous-thromboembolism-vte-prevention-and-treatment-guidelines/
- Fillat, Z.C. y Gonzalez-Juanatey J.R. Conclusiones. COVID-19, del juicio clínico a la evidencia científica. Rev Esp Cardiol [internet]. 2021; 20 (E): 40-42. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668176/
- Corderoa A., Escribanoa D. y Bertomeu-Gonzáleza V. Complicaciones cardiovasculares y pronóstico en pacientes con COVID-19. Rev Esp Cardiol [internet]. 2020; 20 (E) 9-13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668213/
- Paiter Nascimento J.H., Ferraz B. y Moraes G.M. Troponina Cardíaca como Preditor de Injúria Miocárdica e Mortalidade por COVID-19. Arq Bras Cardiol [internet]. 2020; 115 (4): 667-668. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386976/
- Rozadoa J., Ayesta A., Morísa C. y Avanzas P. Fisiopatología de la enfermedad cardiovascular en pacientes con COVID-19. Isquemia, trombosis y disfunción cardiaca. Rev Esp Cardiol [internet]. 2020; 20 (E): 2-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668171/
- Bansal M. Cardiovascular disease and COVID-19. Clinical Research & Reviews [internet]. 2020; 14: 247-250.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102662/
- Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J [internet]. 2020; 41, 1798–1800. https://pubmed.ncbi.nlm.nih.gov/32186331/
- Peretto G, Sala S, Patrizia Caforio A.L. Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement. Eur Heart J [internet]. 2020; 22: 2124–2125. https://academic.oup.com/eurheartj/article/41/22/2124/5828483
- Gouvêa GL., Braga F., Kezen J., Freites Nobre G., Kalichsztein M., Pache de Faria P, et al. Valor Prognóstico da Troponina T e do Peptídeo Natriurético Tipo B em Pacientes Internados por COVID-19. Arq Bras Cardiol [internet]. 2020; 115 (4): 660-665. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386964/
- Dos Santos P., Pérez-Sánchez L., Ocanto A., Oquillas-Izquierdo D. y Rodríguez-Recio, F. Dímero-D elevado y tromboembolismo pulmonar agudo en pacientes con COVID-19. J Negat No Posit Results [internet]. 2020; 5 (12): 1516-1527. https://dialnet.unirioja.es/servlet/articulo?codigo=7802717
- The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic [internet]. 2020. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESCCOVID-19-Guidance.
- Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., et al.Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol [internet]. 2020; 109: 531–538. https://pubmed.ncbi.nlm.nih.gov/32161990/
- Zhou F., Yu T., Du R., Guohui F., Liu Y., Liu Z., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [internet]. 2020; 395 (10229): 1054-106. https://pubmed.ncbi.nlm.nih.gov/32171076/
- Flores A., Kenar M., Villaseca A.B., Ubaldini J., Fernández Cid G., et al. Complicaciones cardiovasculares, trombosis y coagulación en pacientes con COVID-19: “Una ayuda a su entendimiento”. Revista SATI [internet]. 2021; 38: 2-24. https://revista.sati.org.ar/index.php/MI/article/view/749
- Ramírez-Ramos C., Vanegas D., Ramírez-Méndez D., Castilla-Agudelo G., Aranzazu-Uribe A., Fernandez-Rui R., et al. Impacto de COVID-19 en la enfermedad cardiovascular. Revista CES Medicina. 2020; Especial COVID-19: 128-136.
http://www.scielo.org.co/pdf/cesm/v34nspe/0120-8705-cesm-34-spe-128.pdf
- Franco-Moreno A., Muñoz-Rivas N., Mestre-Gómez B. y Torres-Macho J. Tromboembolismo pulmonar y COVID-19: un cambio de paradigma. Rev Clín Esp. 2020; 220(7): 459–461. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7241371/
- Ortiz M., Valencia N., Moreno E., Zafra M., Espinel L., Villareal D., et al. ACV y covid-19: una revisión de los estudios observacionales publicados en época de pandemia. Acta Neurol Colomb. 2020; 36(2): 63-74.
http://www.scielo.org.co/pdf/anco/v36n2/2422-4022-anco-36-02-63.pdf
- Hernández Pérez I., Talavera B., Valle Peñacoba G., y García Azorín D. Síncope aislado como forma de presentación de infección por COVID-19. Neurología. 2021; 36: 169-189.
- Vicente-Herrero M., Ramirez M. y Capdevila-Garcia L. Covid-19: vulnerabilidad estimada en pacientes con factores de riesgo metabolico y cardiovascular. Rev Mex Endocrinol Metab Nutr. 2021; 8 (XX): 1-10.
https://www.revistadeendocrinologia.com/files/rme_002_21_vulnerabilidad_vicente_ar_es-5.pdf